FCSC—I’ve already presented an argument for why laViv won’t garner commercial sales of any consequence. If you’re now looking for a reason why the FDA might not approve the product, you can start with the fact that there is no medical need for another dermal filler to treat nasolabial folds.
Market Data 
Markets 
AI
